Aardvark hininto ang Phase 3 HERO trial ng ARD-101 sa PWS

Kusang-loob na hininto ng kumpanya ang pagpapatala at pagbibigay ng dosis sa Phase 3 HERO at OLE trials ng ARD-101 matapos ang mga reversible cardiac observations sa isang healthy-volunteer study. Nakikipagtulungan ito sa FDA upang matukoy ang mga susunod na hakbang at inaasahang magbibigay ng karagdagang gabay sa Q2 2026. Ang pagpapaunlad ng ARD-201 ay hininto rin.

Mahahalagang fact

Na-file: May 7, 2026, 01:28 PM
Kaganapan: Pagbabago sa trial registry
Direksyon: Negatibo
Kumpanya: AARDAardvark Therapeutics
Asset: ARD-101
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.

SEC 8-K